
Breakthroughs that
See news releases about Etira, our stellar team,


ERX-315 Phase 1 Clinical Trial Update
NewsSydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…

Dr. Raj appointed as Etira Chief Medical Officer
NewsDallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…

First patient dosed in ERX-315-101 Clinical Trial
NewsSydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…

Drs. Jenkins and Stebbing join Etira Board
NewsDallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…

Validation of ERX-208 in Ovarian Cancer
NewsSeattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247